Aster saponin A 2 inhibits osteoclastogenesis through mitogenactivated protein kinase-c-Fos-NFATc1signaling pathway
- Author:
Xiang-Dong SU
1
;
Seo Y YANG
;
Saroj K SHRESTHA
;
Yunjo SOH
Author Information
- Publication Type:Original Article
- From:Journal of Veterinary Science 2022;23(4):e47-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:In lipopolysaccharide-induced RAW264.7 cells, Aster tartaric (AT) inhibits the nuclear factor kappa-light-chain-enhancer of activated B cells and MAPKs pathways and critical pathways of osteoclast development and bone resorption.
Objectives:This study examined how aster saponin A2 (AS-A2) isolated from AT affects the processes and function of osteoclastogenesis induced by receptor activator of nuclear factor kappa-B ligand (RANKL) in RAW264.7 cells and bone marrow macrophages (BMMs).
Methods:The cell viability, tartrate-resistant acid phosphatase staining, pit formation assay, polymerase chain reaction, and western blot were carried out to determine the effects of ASA2 on osteoclastogenesis.
Results:In RAW264.7 and BMMs, AS-A2 decreased RANKL-initiated osteoclast differentiation in a concentration-dependent manner. In AS-A2-treated cells, the phosphorylation of ERK1/2, JNK, and p38 protein expression were reduced considerably compared to the control cells. In RAW264.7 cells, AS-A2 suppressed the RANKL-induced activation of osteoclast-related genes. During osteoclast differentiation, AS-A2 suppressed the transcriptional and translational expression of NFATc1 and c-Fos. AS-A2 inhibited osteoclast development, reducing the size of the bone resorption pit area.
Conclusion:AS-A2 isolated from AT appears to be a viable therapeutic therapy for osteolytic illnesses, such as osteoporosis, Paget’s disease, and osteogenesis imperfecta.
